Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ECTRIMS 2023

11–13 October 2023 | Milan, Italy

ECTRIMS 2023

11–13 October 2023 | Milan, Italy
Distinctive attributes and efficacy of inebilizumab in NMOSD 8:16
Distinctive attributes and efficacy of inebilizumab in NMOSD
Brian Weinshenker • 23 Oct 2023
Baseline characteristics in the HERCULES trial: tolebrutinib in non-relapsing SPMS 2:28
Baseline characteristics in the HERCULES trial: tolebrutinib in non-relapsing SPMS
Erik Wallstroem et al. • 12 Oct 2023
Unlocking clinical potential: autoantibody detection and antigen discovery 2:04
Unlocking clinical potential: autoantibody detection and antigen discovery
Amandine Mathias • 3 Oct 2023
Prospects and challenges in NMOSD treatment 3:04
Prospects and challenges in NMOSD treatment
Brian Weinshenker • 23 Oct 2023
The next steps for tolebrutinib in MS 1:44
The next steps for tolebrutinib in MS
Erik Wallstroem et al. • 12 Oct 2023
NEXT-MS trial: natalizumab personalized extended interval dosing 3:26
NEXT-MS trial: natalizumab personalized extended interval dosing
Alyssa Toorop • 19 Oct 2023
Decoding the genetic predisposition to PML in patients on natalizumab 4:26
Decoding the genetic predisposition to PML in patients on natalizumab
Eli Hatchwell • 24 Oct 2023
White matter disconnectivity and inflammation in MS patients with PRLs 4:02
White matter disconnectivity and inflammation in MS patients with PRLs
Ceren Tozlu • 23 Oct 2023
Predicting relapses in MOGAD 1:17
Predicting relapses in MOGAD
Torge Rempe • 20 Oct 2023
Implications of extended dosing of natalizumab on wearing-off symptoms in MS patients 4:33
Implications of extended dosing of natalizumab on wearing-off symptoms in MS patients
Alyssa Toorop • 19 Oct 2023
Advancements in PML genetic risk assessment 8:18
Advancements in PML genetic risk assessment
Eli Hatchwell • 24 Oct 2023
The prognostic value of PRLs in MS progression 4:40
The prognostic value of PRLs in MS progression
Ceren Tozlu • 23 Oct 2023
Assessing predictors of relapse in MOGAD patients 5:32
Assessing predictors of relapse in MOGAD patients
Torge Rempe • 20 Oct 2023
Refining extended dosing and exploring wearing-off biomarkers 1:23
Refining extended dosing and exploring wearing-off biomarkers
Alyssa Toorop • 19 Oct 2023
A PML risk genetic test to identify at-risk patients on natalizumab 1:50
A PML risk genetic test to identify at-risk patients on natalizumab
Eli Hatchwell • 24 Oct 2023
Rituximab may be less effective in non-Caucasian patients with NMOSD 3:16
Rituximab may be less effective in non-Caucasian patients with NMOSD
Torge Rempe • 20 Oct 2023
The content of VJNeurology is intended for healthcare professionals